Polaprezinc prevents ongoing thioacetamide–induced liver fibrosis in rats.

Kono Toru, Asama Toshiyuki, Chisato Naoyuki, Ebisawa Yoshiaki, Okayama Tsishi, Imai Kouji, Karasaki Hidenori, Furukawa Hiroyuki, Yoneda Masashi
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier’s archiving and manuscript policies are encouraged to visit:

http://www.elsevier.com/copyright
Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats

Toru Kono,a,⁎ Toshiyuki Asama,a Naoyuki Chisato,a Yoshiaki Ebisawa,a Taishi Okayama,a Kouji Imai,a Hidenori Karasakia,b Hiroyuki Furukawaa,b Masashi Yoneda,b

a Division of Gastroenterologic and General Surgery, Department of Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
b Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Aichi Medical University, Nagakute, Aichi 480-1195 Japan

Aim: Cirrhotic patients commonly have a liver zinc deficiency, which may aggravate liver fibrosis due to the lack of antioxidative effects of zinc. This study examined the ability of polaprezinc, N-(3-aminopropionyl)-l-histidinato zinc, to prevent fibrosis in a rat model of thioacetamide (TAA)-induced hepatic fibrosis.

Main methods: Liver cirrhosis was induced by orally administering TAA for 20 weeks. The rats were cotreated with one of the following for the last 10 weeks of TAA treatment: (1) polaprezinc (50 or 200 mg/kg/day); (2) L-carnosine (155 mg/kg/day), which contained equal amounts of L-carnosine as 200 mg/kg/day polaprezinc; (3) zinc sulfate (112 mg/kg/day) or (4) zinc-L-aspartic complex (317.8 mg/kg/day). Both zinc supplementations contained equal amounts of zinc as high-dose polaprezinc.

Key findings: Hepatic zinc levels fell significantly in rats treated with TAA for 20 weeks. Cotreating with high-dose polaprezinc and zinc-L-aspartic complex for 10 weeks prevented hepatic zinc loss. Hepatic hydroxyproline and tissue inhibitor of metalloproteinases-1 (TIMP-1) were significantly lower in rats treated with TAA for 20 weeks than 10 weeks, whereas polaprezinc prevented changes in these fibrosis markers and reduced hepatic transforming growth factor-β1 protein concentration, macroscopic and histologic changes. TAA caused oxidative stress-related changes in the liver that were prevented by high-dose polaprezinc and partially by zinc-L-aspartic complex. Treatment with L-carnosine, low-dose polaprezinc or zinc sulfate for 10 weeks did not affect liver fibrosis progression or oxidative stress-related changes.

Significance: Polaprezinc may prevent ongoing fibrosis by preventing zinc depletion, oxidative stress and fibrosis markers in cirrhotic livers.

⁎ Corresponding author at: Department of Surgery, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan. Tel./fax: +81 166 68 2503/2193.
E-mail address: kono@asahikawa-med.ac.jp (T. Kono).
whether the efficacy of polaprezinc is due to zinc supplementation alone.

In this study, we used a rat model of long-term thioacetamide (TAA)-induced hepatic fibrosis to compare the antioxidative and antifibrotic effects of a continuous supply of different zinc amino acid complexes and zinc sulfate, all contained the same amount of zinc, except for the low-dose polaprezinc, as well as the effects of t-carnosine, a component of polaprezinc.

Materials and methods

Animal treatment and induction of chronic liver damage

Male Wistar rats (aged 5 weeks at the start of the protocols) were used in all experiments. The rats were kept in the animal breeding house at Asahikawa Medical University with free access to food (Purina rodent powder diet CE-2, Hokudo, Sapporo, Japan) and water. All animals received humane care during the study. The experimental protocols were approved by the Animal Care Committee of Asahikawa Medical University and were in accordance with the National Institute of Health’s “Guide for the Care and Use of Laboratory Animals”.

Liver cirrhosis was induced by orally administering TAA (300 mg/L) in the drinking water for 20 weeks as described previously (Muller et al., 1988). The age-matched control animals received normal tap water.

The experimental protocol is illustrated in Fig. 1. Nine groups, each containing 15 animals, were examined. In group 1, TAA was continuously administered for 20 weeks. Starting 10 weeks after the initiation of TAA administration, the animals in groups 2, 3, 4, 5 and 6 were also administered the following in their powdered food for 10 weeks: polaprezinc (50 mg/kg/day, zinc 11.3 mg or 200 mg/kg/day, zinc 45.2 mg; Zeria Shinyaku Pharmaceutical Co., Ltd., Tokyo, Japan); zinc sulfate (112 mg/kg/day, zinc 45.2 mg; Wako Pure Chemical Industries, Osaka, Japan); zinc-L-aspartic chelate complex (317.8 mg/kg/day, zinc 45.2 mg; Zinc100; KAL, Knoxville, TN, USA); or L-carnosine (155 mg/kg/day, NOW, Bloomingdale, IL, USA), which contained equal amounts of t-carnosine as polaprezinc 200 mg/kg/day. Zinc sulfate and zinc-L-aspartic complex contained equal amounts of zinc ions as polaprezinc (200 mg/kg/day). The rats in group 7 were sacrificed after 10 weeks of TAA administration. The rats in group 8 received no drug treatment during the 20-week experimental period. The rats in group 9 received polaprezinc (500 mg/kg/day) for the last 10 weeks of the experimental period. Body weight and food intake were monitored weekly and daily throughout the experimental period, respectively. At the end of the experimental period, the rats were anesthetized with sodium pentobarbital (50 mg/kg). Blood was drawn using a heparinized syringe from the abdominal aorta, and serum was obtained by centrifugation.

Analysis of the zinc content in the liver

At the end of the study period, liver tissue was obtained from the rats in each group, frozen in liquid nitrogen, and stored at −80 °C. The zinc concentration in each sample was determined using an absorption spectrophotometer (Z-6110, Hitachi, Tokyo, Japan).

Assessment of liver fibrosis

At the end of the study period, the resected livers were either fixed overnight in 4% paraformaldehyde in phosphate-buffered saline at 4 °C or frozen immediately in liquid nitrogen. Serial 5-μm sections were prepared after the samples had been dehydrated in graded ethanol solutions, cleared in chloroform, and embedded in Paraplast (Fisher Scientific Japan, Tokyo, Japan). Collagenous and noncollagenous proteins were differentially stained with 0.1% Sirius Red using 0.1% Fast Green as a counterstain in saturated picric acid in order to conduct a semiquantitative morphometric analysis of liver fibrosis using an image analysis system (Nikon Digital Sight DS-L1, Tokyo, Japan). The percentage of area that was stained with Sirius Red at a 40× magnification and the mean percentage area for each sample were calculated.

Fig. 1. Experimental protocol. Rats were divided into 9 groups of 15 animals each. In groups 1–6, thioacetamide (TAA) was administered continuously for 20 weeks. The rats in group 7 were administered TAA for 10 weeks. In addition to TAA, the animals in groups 2, 3, 4, 5, and 6 received polaprezinc (50 mg/kg/day or 200 mg/kg/day), zinc sulfate (112 mg/kg/day), zinc-L-aspartic complex (317.8 mg/kg/day) and L-carnosine (155 mg/kg/day) in their powdered food for the final 10 weeks of the experiment, respectively. The rats in group 8 received no drug treatment. The rats in group 9 received polaprezinc at 500 mg/kg/day only for the last 10 weeks of the experimental period.
The levels of α-smooth muscle actin (SMA), a specific marker of hepatic stellate cell (HSC) activation, in the liver were detected by immunohistochemistry using an anti-SMA antibody (Sigma, St. Louis, MO, USA). The Vectastain avidin–biotin kit (Vector Laboratories, Burlingame, CA, USA) was used according to the manufacturer’s instructions.

For a semiquantitative morphometric analysis, we assessed the mean value of the area of SMA-positive cells in three visual fields per specimen as the percent area at a 40× magnification using an image analysis system (NIH image 1.62, Bethesda, MD, USA). The SMA-positive cells were expressed as a percentage of the total specimen area.

Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) were assessed using routine laboratory methods.

The collagen concentration was determined by digesting fresh liver samples with acid and then measuring the hepatic hydroxyproline (HP) content (Sakaida et al., 1996). The liver specimens were weighed, and 20 mg of frozen sample was autoclaved in 6 M HCl for 24 h. After centrifugation, the supernatant was mixed with 1% phenolphtalein and 8N KOH to obtain a solution with pH 7 to 8. This solution was stirred with chloramidine T solution for 60 min at 0 °C. The resulting solution was stirred with KCl and borate buffer (pH 8.2) for 15 min at room temperature and for another 15 min at 0 °C. After adding 3.6 M sodium thiosulfate, the solution was incubated for 30 min at 120 °C and stirred with toluene for 20 min. The reaction was centrifuged at 2000 rpm at 4 °C and the precipitation was added to the resulting supernatant. The final product was incubated for 30 min at room temperature. The absorbance at 560 nm was measured, and the HP content was expressed in μg/g of wet liver.

Hepatic TGF-β1 protein concentration was measured by the Predicta assay kit (Genzyme Diagnostics, Cambridge, MA, USA) after determining total hepatic protein content with BSA (Sakaida et al., 1998). All TGF-β1 protein levels were assessed as the active form by the addition of HCl. The total liver protein content was determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). TGF-β1 protein concentration was expressed as ng/g of total liver protein.

Assessment of overall extent of fibrinolysis in liver

For the study of MMP activity, frozen liver samples were mechanically homogenized and centrifuged and clarified supernatant were used for protein quantification by Bradford method. Aliquots (30 μg protein) from liver extracts were subjected to electrophoresis in SDS-PAGE gels under non-reducing conditions. The gelatin substrate was present at 0.1% final concentration in the gel. The gels were electrophoresed at 100 V for 2 h at 4 °C in a Bio-Rad MiniProtein II system (Bio-Rad Laboratories, Inc., Richmond, CA, USA). Following electrophoresis, gels were washed by gentle shaking at room temperature with 2.5% Triton X-100 (two changes) for 1 h. The gels were incubated for 24 h in 50 mM Tris–HCl (pH 8.4) containing 5 mM CaCl2 and 1 mM ZnCl2 at 37 °C. After incubation, gels were stained by Coomassie Brilliant Blue R-250. Areas of proteolysis appeared as clear zones against a blue background. Molecular mass determinations were made with reference to prestained protein standards (Bio-Rad Laboratories) co-electrophoresed into the gels. The integrated optical density (IOD) spectrophotometry was determined in an image analysis system (NIH image 1.62, Bethesda, MD, USA). The values of IOD were analyzed statistically and plotted in histograms.

For the detection of tissue inhibitor of MMP (TIMP) in liver, enzyme-linked immunosorbent assay (ELISA) was used. Frozen liver samples were mechanically homogenized and centrifuged, and protein extracted on supernatant was quantified by Bradford method. The supernatants were quantified by the Quantikine immunoassay kits from R&D systems raised against rat TIMP-1 (Wako, Osaka, Japan) by following the instructions provided by the manufacturers. The absorbances at 450 nm were measured in a microtest plate spectrophotometer (Immuno Mini NJ-2300, Biotec, Tokyo, Japan), and antigen levels were determined by appropriate calibration curves.

Assessment of oxidative stress-related parameters in the liver

Oxidative stress was evaluated based on the levels of lipid peroxide (LPO), superoxide dismutase (SOD) activity and reduced glutathione (GSH) in the liver. LPO and SOD were measured using the LPO-586 and SOD-525 commercial assay kits, respectively (Bioxytec, Portland, OR, USA). LPO and SOD were measured in liver homogenates following the manufacturer’s guidelines, as previously described (Sun et al., 1988; Zhou et al., 2001). The GSH-400 commercial kit (Bioxytec) was used to measure GSH in liver extracts.

Statistical analysis

Data from each experimental group are expressed as the means ± SD. Multiple group comparisons were performed by Kruskal–Wallis one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test. P-values < 0.05 were considered statistically significant.

Results

The body weight and daily food intake are shown in Table 1. The starting weight did not differ among the groups. TAA caused a marked decrease in total body weight in all the groups except for the normal control group. However, cotreatment with polaprezinc (200 mg/kg/day) and zinc complex attenuated this change in body weight. By contrast, treatment with zinc sulfate exacerbated this change in body weight and also resulted in reduced daily food intake compared to other groups. Among rats that were treated with TAA for 20 weeks, the hepatic zinc levels started to fall at 10 weeks and were significantly lower at 20 weeks than those of the controls (from 39.5 ± 3.5 μg/g to 24.2 ± 4.6 μg/g, P < 0.01). However, the hepatic zinc content was significantly higher in animals cotreated with oral polaprezinc (200 mg/kg/day) and zinc-α-aspartic complex (34.5 ± 5.2 μg/g and 32.8 ± 7.2, P < 0.01).

Table 1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Start</th>
<th>5 weeks</th>
<th>10 weeks</th>
<th>15 weeks</th>
<th>20 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>119 ± 4.2</td>
<td>253 ± 5.7</td>
<td>318 ± 9.6</td>
<td>357 ± 14.4</td>
<td>388 ± 15.3</td>
</tr>
<tr>
<td>TAA 10 weeks</td>
<td>120 ± 3.0</td>
<td>187 ± 7.6</td>
<td>218 ± 11.5</td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td>TAA 20 weeks</td>
<td>119 ± 3.8</td>
<td>181 ± 11.4</td>
<td>222 ± 18.3</td>
<td>233 ± 26.7</td>
<td>239 ± 28.0</td>
</tr>
<tr>
<td>TAA 20 weeks + polaprezinc 50</td>
<td>120 ± 4.0</td>
<td>182 ± 9.8</td>
<td>219 ± 13.4</td>
<td>235 ± 26.3</td>
<td>242 ± 27.0</td>
</tr>
<tr>
<td>TAA 20 weeks + polaprezinc 200</td>
<td>120 ± 4.0</td>
<td>182 ± 9.8</td>
<td>219 ± 13.4</td>
<td>235 ± 26.3</td>
<td>242 ± 27.0</td>
</tr>
<tr>
<td>TAA 20 weeks + zinc sulfate</td>
<td>118 ± 3.7</td>
<td>181 ± 10.8</td>
<td>217 ± 16.3</td>
<td>245 ± 22.9</td>
<td>259 ± 20.1</td>
</tr>
<tr>
<td>TAA 20 weeks + zinc complex</td>
<td>118 ± 3.7</td>
<td>181 ± 10.8</td>
<td>217 ± 16.3</td>
<td>245 ± 22.9</td>
<td>259 ± 20.1</td>
</tr>
<tr>
<td>TAA 20 weeks + i-carnosine</td>
<td>119 ± 3.8</td>
<td>182 ± 10.5</td>
<td>220 ± 15.4</td>
<td>227 ± 25.6</td>
<td>224 ± 28.4</td>
</tr>
<tr>
<td>Polaprezinc 500</td>
<td>120 ± 4.1</td>
<td>256 ± 6.4</td>
<td>319 ± 10.4</td>
<td>356 ± 12.7</td>
<td>386 ± 13.8</td>
</tr>
</tbody>
</table>

Note: Results are expressed as the means ± SD (n = 15). The controls received no drug treatment. The remaining groups received 300 mg/L thioacetamide (TAA) in their drinking water for 10 or 20 weeks. Six groups of rats were also cotreated with oral polaprezinc (50 or 200 mg/kg/day), zinc sulfate (112 mg/kg/day), zinc-L-aspartic complex (317.8 mg/kg/day) or i-carnosine (155 mg/kg/day) after 10 weeks of TAA monotherapy. The polaprezinc 500 group only received polaprezinc (500 mg/kg/day) and also resulted in reduced daily food intake compared to other groups.

* P < 0.01 versus control.
** P < 0.05 versus TAA 20 weeks.
respectively) than in rats treated with TAA alone for 20 weeks, and these levels were close to the 10-week TAA value (37.1 ± 5.4 μg/g). There were no significant differences between the groups that received polaprezinc (200 mg/kg/day) and zinc-L-aspartic complex (Fig. 2).

Fig. 3 shows representative photographs of the gross appearance of the liver after 10 and 20 weeks of TAA treatment alone, and after polaprezinc was added to the treatment regimen for the last 10 weeks of TAA administration. Among rats treated with TAA alone, the hepatic surface was slightly rough at 10 weeks, indicating that hepatic fibrosis had already developed. At 20 weeks, large nodules were observed on the surface of the liver, indicating that cirrhosis had developed by this stage. Rats cotreated with polaprezinc (200 mg/kg/day) had decreased hepatic fibrosis progression after 10 weeks of TAA treatment. However, L-carnosine cotreatment did not prevent the progression of liver fibrosis.

The degree of hepatic fibrosis was confirmed by histologically examining Picrosirius Red-stained liver sections (Fig. 3). In the age-matched control rats, there was no spontaneous hepatic fibrosis. In the group treated with TAA for 10 weeks, mild but noticeable fibrosis developed in the liver, which was consistent with the macroscopic appearance of the liver. In the group treated with TAA for 20 weeks, there was a marked increase in the extracellular matrix collagen content and bridging fibrosis was prominent. There were bundles of collagen surrounding the lobules that resulted in large fibrous septa and distorted tissue architecture. In sharp contrast, only mild fibrotic changes were detected at 20 weeks in the polaprezinc group. These changes were similar to those seen after 10 weeks of TAA monotherapy. Semiquantification of collagen deposition in the liver showed that rats treated with TAA for 20 weeks (19.3 ± 5.2%) had significantly higher collagen deposition than that of the control rats (0.8 ± 0.4%) and rats treated with TAA for 10 weeks (6.5 ± 1.5%). High doses of polaprezinc (200 mg/kg/day) significantly prevented the progression of TAA-induced fibrosis (6.8 ± 1.5%), but this was not observed in the groups cotreated with low-dose polaprezinc (17.3 ± 2.9%), zinc sulfate (17.4 ± 4.8%), zinc complex (14.7 ± 3.3%) or L-carnosine (19.2 ± 4.6%) (Fig. 4A).

Fig. 3 also shows the hepatic expression of SMA. Positive SMA staining was clearly detected along the sinusoidal endothelium in the hepatic lobules in the TAA-treated groups. Very few SMA-positive cells were found in the sinusoidal walls in the control animals, although the portal area contained SMA-positive vessels, which were thought to be hepatic arteries. Semiquantification of SMA-positive cells showed that the number of SMA-positive cells significantly increased during the latter 10-week treatment period (control, 0.3 ± 0.1%; 10-week TAA, 1.2 ± 0.5%; 20-week TAA, 4.3 ± 1.5%). However, this increase in SMA expression was significantly inhibited in rats that were cotreated with high-dose polaprezinc (200 mg/kg/day) (1.3 ± 0.5%), but not low-dose polaprezinc (3.9 ± 1.4%), zinc sulfate (4.0 ± 2.1%), zinc complex (3.0 ± 1.6%) or L-carnosine (4.4 ± 1.7%) (Fig. 4B).

To evaluate hepatic collagen production after chronic TAA administration, hepatic HP was analyzed (Fig. 5). HP markedly increased in rats that were treated with TAA for 20 weeks (707 ± 223.1 μg/g), and this increase was significantly greater than that in the control group (92 ± 36.2 μg/g) and animals treated with TAA for 10 weeks (199 ± 62.7 μg/g). The increase in HP during the latter 10 weeks of TAA administration was significantly prevented in rats cotreated with polaprezinc during this period (200 mg/kg/day) (156 ± 65.5 μg/g). Cotreatment with low-dose polaprezinc (410 ± 207.1 μg/g), zinc sulfate (607 ± 280.4 μg/g), zinc-L-aspartic complex (307 ± 53.8 μg/g) or L-carnosine (518 ± 236.1 μg/g) did not prevent this increase in HP. Fig. 6 shows hepatic TGF-β1 protein concentration. Hepatic TGF-β1 protein concentration remarkably increased in the 10-week TAA treatment group (69.9 ± 17.6 ng/mg) from the control level (7.4 ± 1.4 ng/mg), and declined but maintained a significant increase in the 20-week TAA treatment group (34.5 ± 11.9 ng/mg) compared to the control level. This increase of hepatic TGF-β1 protein concentration was significantly prevented in rats cotreated with polaprezinc during this period (200 mg/kg/day) (17.3 ± 4.7 ng/mg). However, cotreatment with low-dose polaprezinc (28.2 ± 8.4 μg/mg), zinc sulfate (31.3 ± 11.8 μg/mg), zinc-L-aspartic complex (22.7 ± 7.1 μg/mg) or L-carnosine (32.3 ± 8.5 μg/mg) did not reduce the hepatic TGF-β1 protein concentration.

Data regarding MMP-2 and -9 activities are shown in Fig. 7. A significant increase in the activity of active MMP-2 (59 kDa) occurred in rats treated with TAA for 20 weeks (3.9 ± 2.0 arbitrary units), and this increase was significantly greater than that in animals treated with TAA for 10 weeks (1.7 ± 0.4 arbitrary units). The increase in MMP-2 activity during the latter 10 weeks of TAA administration was not observed in rats cotreated with polaprezinc during this period (50 and 200 mg/kg/day) (1.2 ± 0.4 and 1.1 ± 0.7 arbitrary units), respectively. Cotreatment with zinc sulfate (4.5 ± 2.3 arbitrary units), zinc-L-aspartic complex (3.3 ± 2.6 arbitrary units) or L-carnosine (6.7 ± 3.2 arbitrary units) resulted in an increase in MMP-2 activity. Pro-MMP-2 (72 kDa) activity also showed a similar trend of pro-MMP-2 activity in liver. Pro-MMP-9 (92 kDa) was significantly higher in all groups than in normal rats. However, there were no significant differences among the groups.

As shown in Fig. 8, TAA treatment caused a marked and time-dependent increase in the amount of TIMP-1 protein levels (from 1427 ± 321 pg/ml to 5467 ± 321 pg/ml after TAA 10 weeks, and to 12,733 ± 306 pg/ml after TAA 20 weeks). Polaprezinc cotreatment caused a gradual and dose-dependent decrease in the amount of TIMP-1 protein from the starting point of polaprezinc cotreatment (from 5467 ± 321 pg/ml to 3033 ± 115 pg/ml after low-dose polaprezinc, and to 1867 ± 208 pg/ml after high-dose polaprezinc). High-dose polaprezinc decreased the level of TIMP-1 protein to the control level. Zinc-L-aspartic complex significantly decreased the level of TIMP-1 protein in the control level. Zinc-L-aspartic complex prevented the increase of TIMP-1 protein (4900 ± 100 pg/ml). However, cotreatment with L-carnosine and zinc sulfate, the increased the TIMP-1 protein levels to 13,367 ± 839 and 13,833 ± 737 pg/ml, respectively, which were comparable to the levels seen in rats treated with TAA for 20 weeks.

As shown in Table 2, TAA administration for 10 and 20 weeks significantly increased hepatic LPO, which was significantly inhibited by
cotreatment with high-dose polaprezinc. In contrast, LPO was not affected by cotreatment with low-dose polaprezinc, zinc sulfate, zinc-\(\ell\)-aspartic complex or \(\ell\)-carnosine. GSH and SOD in the liver were significantly reduced in both TAA-treated groups. Cotreatment with high-dose polaprezinc significantly inhibited these changes in the TAA-treated animals, and zinc-\(\ell\)-aspartic complex cotreatment significantly inhibited the TAA-induced reduction in GSH, but not SOD (Table 2). Cotreatment with low-dose polaprezinc, zinc sulfate or \(\ell\)-carnosine did not affect the TAA-induced reduction in GSH.

The serum levels of ALT and AST did not change significantly during the development of liver cirrhosis in any of the groups except for the group treated with TAA for 10 weeks (Table 3). The serum ALP levels steadily increased in TAA-treated rats at both 10 and 20 weeks. Cotreatment with high-dose polaprezinc (200 mg/kg/day) significantly inhibited this increase in ALP. Furthermore, very high-dose polaprezinc (500 mg/kg/day) monotreatment did not alter the serum ALT, AST and ALP levels.

**Discussion**

It is critical to prevent fibrosis in chronic liver disease. Once cirrhosis is established, patients are at increased risk of developing liver injury, portal hypertension and carcinomas (Bataller and Brenner, 2005; Friedman, 2003). Cytokines and oxidative stress are thought to induce fibrosis that results from the activation of stellate cells (Cruz et al., 2005; Salguero Palacios et al., 2008). Indeed, free radical generation, mitochondrial dysfunction and antioxidant depletion contribute to the progression of fibrosis and cirrhosis (Natarajan et al., 2006). TAA is widely used to induce liver cirrhosis in rats and the resulting disease is similar to human cirrhosis (Muller et al., 1988; Natarajan et al., 2006; Strnad et al., 2008). TAA is metabolically activated to thioacetamide sulfoxide and further to thioacetamide-S,S-dioxide, and the toxic effects of TAA are attributed to these reactive metabolites (Chilakapati et al., 2007; Chilakapati et al., 2005). TAA-induced liver cirrhosis is associated with lipid peroxidation and the depletion of antioxidants (Abul et al., 2002; Low et al., 2004; Sanz et al., 2002; Sun et al., 2000). Accordingly, reducing oxidative stress appears to facilitate the regression of fibrosis and cirrhosis. Thus, several previous studies have suggested that radical scavengers and antioxidants can be used to prevent TAA-induced liver fibrosis (Balkan et al., 2001; Bruck et al., 2001; Cruz et al., 2005; Hsieh et al., 2008).

Polaprezinc, a zinc-\(\ell\)-carnosine complex, has been clinically used as an antifibrotic agent to treat chronic hepatitis in Japan (Abul et al., 2002; Himoto et al., 2007; Low et al., 2004; Matsuoka et al., 2009; Murakami et al., 2007; Sanz et al., 2002; Sun et al., 2000; Takahashi et al., 2007), although the precise antifibrotic mechanisms of polaprezinc are not fully understood. Polaprezinc treatment has been shown to attenuate fibrosis due to reduced lipid peroxidation, suppressed hepatic stellate cell activation and inhibited mRNA expression of pro-inflammatory cytokines (Sugino et al., 2008). Polaprezinc is comprised of approximately 22.4% (w/w) zinc and 77.6% (w/w) \(\ell\)-carnosine (Yamaguchi et al., 1996). Although both zinc and carnosine have radical scavenging and antioxidant activities (Bray and Betger, 1990; Hippius and Brownson, 2000; Prasad, 2009), many researchers believe that zinc is the main active agent in polaprezinc that impacts the development of liver fibrosis. In this study, carnosine did not attenuate fibrosis, based on its lack of effect on liver HP levels and histopathological findings. A recent study further supported these observations using more than a 12-fold higher dose of L-carnosine than was used in our studies (Aydin et al., 2010).

It is important to compare the antioxidative effects and antifibrotic effects across the different zinc amino acid complexes and zinc sulfa, all of which contain the same amount of zinc, to determine whether the effects of the complex are important or whether it is a
zinc-specific effect. The dose of zinc sulfate used in this study was approximately half of that used in previous liver fibrosis animal model studies (Dashti et al., 1997; Gimenez et al., 1994; Sidhu et al., 2005; Song and Chen, 2003). Therefore, it is possible that the dose used in this study was not sufficient to mediate these antioxidative and anti-fibrotic effects. However, we found that this dose suppressed diet-associated weight gain in the zinc sulfate-treated group. This might be due to the adverse effects of zinc sulfate on the gastrointestinal system (Samman and Roberts, 1987), and this side effect should be considered when zinc sulfate is clinically administered.

Furthermore, our comparisons of the different zinc amino acid complexes and zinc sulfate indicated that zinc-L-carnosine complex had the greatest antioxidative and anti-fibrotic effects. A recent study clearly showed that zinc ions in zinc complexes had superior antioxidant effects than that of zinc salts, including the zinc sulfate (Pavlica and Gebhardt, 2010). Moreover, polaprezinc and Zn-SOD have been shown to have similar structures (Yoshikawa et al., 1991a). Thus, polaprezinc may act as an antioxidant in cirrhotic livers, although the precise mechanisms of action are unclear.

To date, the relationship between the effects of zinc ions on membrane stabilization and antioxidation remain unclear. Polaprezinc may provide significant protection compared to the lack of protection that is achieved with zinc-L-aspartic complex and zinc sulfate because polaprezinc binds more tightly to membrane lipids (Pavlica and Gebhardt, 2010). This is in good agreement with the reported observation that zinc ions obtained from a zinc complex stabilized peroxidized membranes and minimized their peroxidative damage, resulting in a retained membrane structure rather than a decrease in the levels of oxidant formation (Pavlica and Gebhardt, 2010). Both zinc complexes significantly inhibited TAA-induced LPO production in...
the liver. However, the precise mechanism by which polaprezinc inhibits hepatic LPO could not be ascertained from the present study.

The cirrhotic rat liver has been shown to have decreased zinc levels (Marchesini et al., 1996). In addition, the levels of zinc in liver tissue are significantly lower in cirrhotic patients than in healthy controls (Capocaccia et al., 1991). Intestinal zinc absorption has been found to be significantly reduced in cirrhotic patients and to correlate with the degree of liver dysfunction (Solis-Herruzo et al., 1989). The rate of zinc absorption from polaprezinc is approximately 11% in rats, which is comparable to that of zinc-γ-aspartic complex (Sano et al., 1991). In this study, zinc deficiency was restored by administering polaprezinc or zinc-γ-aspartic complex and these treatments did not result in zinc overdosing. In addition, there were no differences in the hepatic zinc content between the groups that received polaprezinc and zinc-γ-aspartic complex, but polaprezinc treatment resulted in significantly greater preventative effects than zinc-γ-aspartic complex based on serum markers, hepatic fibrotic markers, and liver histology. These findings might indicate that the effects of the complex, especially for γ-carnosine complex, are more important than zinc supplementation alone.

SMA expression is reportedly a biomarker of HSC activation and activated HSCs are the main source of TGF-β1 (Gressner et al., 2002; Tsukada et al., 2006). TGF-β1 is one of the most powerful profibrogenic mediators in the liver and increased levels of TGF-β1 have been found both in patients with liver fibrosis and in experimental models (Chen et al., 2002; Salguero Palacios et al., 2008). Interestingly, the maximal expression of transiently elevated TGF-β1 was observed which is in accordance with previous results using TAA-treated animals (Salguero Palacios et al., 2008). The blockade of

Table 2

<table>
<thead>
<tr>
<th>Treatment</th>
<th>LPO (μmol/g)</th>
<th>GSH (μmol/g)</th>
<th>SOD (U/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5.5 ± 2.0</td>
<td>6.4 ± 1.3</td>
<td>11.6 ± 3.5</td>
</tr>
<tr>
<td>TAA 10 weeks</td>
<td>9.1 ± 1.1</td>
<td>3.2 ± 0.8</td>
<td>5.0 ± 1.9</td>
</tr>
<tr>
<td>TAA 20 weeks</td>
<td>11.4 ± 2.9</td>
<td>1.7 ± 0.5</td>
<td>4.3 ± 2.8</td>
</tr>
<tr>
<td>TAA 20 weeks + polaprezinc 50</td>
<td>9.3 ± 2.7</td>
<td>2.0 ± 0.6</td>
<td>5.6 ± 3.0</td>
</tr>
<tr>
<td>TAA 20 weeks + polaprezinc 200</td>
<td>6.3 ± 2.7**</td>
<td>6.1 ± 1.2**</td>
<td>10.4 ± 4.0**</td>
</tr>
<tr>
<td>TAA 20 weeks + zinc sulfate</td>
<td>10.6 ± 3.6</td>
<td>1.9 ± 0.7</td>
<td>6.3 ± 4.1</td>
</tr>
<tr>
<td>TAA 20 weeks + zinc complex</td>
<td>8.4 ± 3.7</td>
<td>3.8 ± 1.4***</td>
<td>8.6 ± 4.1</td>
</tr>
<tr>
<td>TAA 20 weeks + L-carnosine</td>
<td>11.1 ± 3.8</td>
<td>1.8 ± 0.9</td>
<td>4.7 ± 3.7</td>
</tr>
</tbody>
</table>

Note: The controls received no drug treatment. The remaining groups received 300 mg/L thioacetamide (TAA) in their drinking water for 10 or 20 weeks. Six groups of rats were also cotreated with polaprezinc (50 or 200 mg/kg/day), zinc sulfate (112 mg/kg/day), zinc-γ-aspartic complex (317.8 mg/kg/day) or L-carnosine (155 mg/kg/day) after 10 weeks of TAA monotherapy. Data are expressed as the means ± SD. Each group contained 15 rats. Abbreviations: TAA, thioacetamide; LPO, lipo peroxide; GSH, reduced glutathione; SOD, superoxide dismutase; U, activity units. *p < 0.01 versus the control.
**p < 0.01.
***p < 0.05 versus TAA 20 weeks.
TGF-β1 synthesis is one of the primary targets for the development of antifibrotic approaches (Gressner et al., 2002). Polaprezinc treatment prevents both the activation of HSCs, which are stained with an anti-SMA antibody only upon activation, and the increase of TGF-β1 content in the TAA treatment liver. It has been reported that zinc deficiency results in a depletion of intracellular glutathione in HSCs followed by the subsequent activation of HSCs that triggers collagen synthesis (Kojima-Yuasa et al., 2003). Recent report suggested that polaprezinc could be used as an immunosuppressive agent through its inhibitory effect on calcineurin activity which plays a crucial role in cytokine expression (Zhang et al., 2011), although the precise mechanism responsible for this reduction remains uncertain, an antifibrotic effect can be achieved through the down-regulation of TGF-1.

In a toxicity study with polaprezinc-treated rats, the toxic effects of polaprezinc became apparent at doses of 600 mg/kg/day (zinc, 134.4 mg/kg/day) or more (Yamaguchi et al., 1996). Therefore, we selected a very high-dose of 500 mg/kg/day (zinc, 102 mg/kg/day) in order to determine the adverse effects that result from treatment with polaprezinc over a long period. Fortunately, this dose of polaprezinc did not result in any adverse effects, and high-dose polaprezinc did not affect body weight. Thus, our findings indicate that polaprezinc may be administered over a long period to patients with chronic liver disease.

Conclusions

In conclusion, our results strongly suggest that polaprezinc can be safely administered during ongoing liver fibrosis to inhibit the progression of liver fibrosis. Polaprezinc prevents oxidative stress and HSC activation in the liver, leading to a reduction in the liver HP, TIMP-1 and TGF-β1 contents that are proportional to the reduction in collagen production.

Conflict of interest statement

No conflict of interest.

Acknowledgments

T. Asama and T. Kono contributed equally to this manuscript. We thank Dr. Reo Nozaki, Dr. Shougo Tamura and Mr. Yoshiyasu Satake for their skilful technical assistances and Mr. Satoru Kubota for helpful advice. This study was supported in part by a grant-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (16659346).

References


### Table 3

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ALT (U/L)</th>
<th>AST (U/L)</th>
<th>ALP (U/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>50 ± 3.1</td>
<td>83 ± 4.8</td>
<td>519 ± 81</td>
</tr>
<tr>
<td>TAA 10 weeks</td>
<td>74 ± 10.6</td>
<td>123 ± 19.6</td>
<td>960 ± 196</td>
</tr>
<tr>
<td>TAA 20 weeks</td>
<td>47 ± 3.7</td>
<td>95 ± 7.3</td>
<td>1439 ± 384</td>
</tr>
<tr>
<td>TAA 20 weeks + polaprezinc 50</td>
<td>48 ± 2.8</td>
<td>93 ± 5.2</td>
<td>1191 ± 251</td>
</tr>
<tr>
<td>TAA 20 weeks + polaprezinc 200</td>
<td>49 ± 2.8</td>
<td>92 ± 6.4</td>
<td>878 ± 172</td>
</tr>
<tr>
<td>TAA 20 weeks + zinc sulfate</td>
<td>51 ± 3.2</td>
<td>95 ± 5.9</td>
<td>951 ± 212</td>
</tr>
<tr>
<td>TAA 20 weeks + zinc complex</td>
<td>50 ± 4.1</td>
<td>94 ± 6.5</td>
<td>1006 ± 145</td>
</tr>
<tr>
<td>TAA 20 weeks + i-carnosine</td>
<td>51 ± 3.2</td>
<td>93 ± 2.9</td>
<td>1251 ± 365</td>
</tr>
<tr>
<td>Polaprezinc 500</td>
<td>51 ± 5.2</td>
<td>85 ± 7.4</td>
<td>524 ± 60</td>
</tr>
</tbody>
</table>

Note: Results are expressed as the means ± SD (n = 15). The controls received no drug treatment. The remaining groups received 300 mg/L thioacetamide (TAA) in their drinking water for 10 or 20 weeks. Six groups of rats were also cotreated with polaprezinc (50 or 200 mg/kg/day), zinc sulfate (112 mg/kg/day), zinc-i-aspartic complex (317.8 mg/kg/day) or i-carnosine (155 mg/kg/day) after 10 weeks of TAA monotherapy. The polaprezinc 500 group only received polaprezinc (500 mg/kg/day) after 10 weeks. Abbreviations: TAA, thioacetamide; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase. *p < 0.05 versus the control. **p < 0.01 versus TAA 20 weeks.
Chilakapati J, Shankar K, Korrapati MC, Hill RA, Mehdende HM. Saturation toxico-
kinetics of thioacetamide: role in initiation of liver injury. Drug Metab Dispos
2003;31:1877–85.
Toxicokinetics and toxicity of thioacetamide sulfide: a metabolite of thioacet-
Consolo M, Amoroso A, Spandolis DA, Mazzarino MC. Matrix metalloproteinases and
their inhibitors as markers of inflammation and fibrosis in chronic liver disease
Melatonin prevents experimental liver cirrhosis induced by thioacetamide in rats.
Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol 2003;38(Suppl. 1):
S28–S36.
collagenolytic activity in carbon-tetrachloride-injured rats: beneficial effects of zinc
Gressner AM, Weisnkirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic
A novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-L-histidinato zinc.
Hoffman J, Weiland C. Protective and anti-inflammatory effects of zinc and iron on
Kisseleva T, Brenner DA. Mechanisms of hepatic fibrosis and cirrhosis in mice.
of a novel ROS scavenging system of GSH in carbon tetrachloride-induced liver
of a novel ROS scavenging system of GSH in carbon tetrachloride-induced liver
Low TY, Leow CK, Salto-Tellez M, Chung MC. A proteomic analysis of thioacetamide-
Mohanty A, Shankar K, Korrapati MC, Hill RA, Mehendale HM. release of oxidative
stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis
and necrosis caused by thioacetamide in rat liver. Biochim Biophys Acta 2000;1500:
804–17.
Nair R, Tillo M, Suresh D, Mathew P. Protective effects of zinc on oxidative stress enzymes in
Prasad AS. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin
Sakaida I, Matsumura Y, Kobata M, Kayano K, Takenaka K, Okita K. The prolyl 4-
hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procolla-
gen expression in rat liver fibrosis induced by choline-deficient L-amino acid
Sakaida I, Uchida K, Matsumura Y, Okita K. Interferon gamma treatment prevents
procollagen gene expression without affecting transforming growth factor-beta1
Salgueso Palacios R, Roderfeld M, Hemmann S, Rath T, Atanasova S, Tuschchner A,
et al. Activation of hepatic stellate cells is associated with cytokine expression in
Sammar S, Roberts DC. The effect of zinc supplements on plasma zinc and copper
levels and the reported symptoms in healthy volunteers. Med J Aust 1987;146:
246–9.
fate of catena-(S)-[μ-N-alpha-(3-aminopropionyl)histidinato(2-)-N1, N2, O:N1]zinc. 1st communication: absorption, distribution, metabolism and excretion
after single oral administration of zinc picolinate in cynomolgus monkeys. Jpn J Nutr
Sanz N, Diez-Fernandez C, Andres D, Cascades M. Hepatotoxicity and aging: endogenous
antioxidant systems in hepatocytes from 2- to 6-, 12-, 18- and 30-month-old rats fol-
Seltzer J, Jeffrey J, Eisen AZ. Evidence for mammalian collagenases as zinc ion metal-
Sidhu P, Garg ML, Ohawan DK. Protective effects of zinc on oxidative enzymes in
Solis-Herruzo J, De Cuenca B, Munoz-Rivero MC. Intestinal zinc absorption in cirrhotic
Song YM, Chen MD. Zinc supplementation attenuates thioacetamide-induced liver
Stamoulis J, Kouraklis G, Theocharis S and Zinc and the liver: an active interaction. Dig Dis
Strnad P, Tao GZ, Zhou Q, Harada M, Toivola DM, Brunt EM, et al. Keratin mutation pre-
disposes to mouse liver fibrosis and unmasks differential effects of the carbon tet-
Sun Y, Oberyew LW, Li Y. A simple method for clinical assay of supersaturated dis-
stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis
and necrosis caused by thioacetamide in rat liver. Biochim Biophys Acta 2000;1500:
181–5.
supplementation on hepatic fibrosis through downregulation of TIMP-1: a pilot study.
23–30.
Yamaguchi I, Shibata K, Takei M, Matsuda K. Changes in tissue contents of zinc, copper
and iron in rats and beagle dogs treated with polaprezinc. J Toxicol Sci 1996:21:
177–87.
Yoshikawa T, Naito Y, Tanigawa T, Yoneta T, Kondo M. The antioxidant properties of a novel
zinc-carnosine chelate compound, N-[3-(aminomethyl)phenyl][3-(aminomethyl)phenyl]-
carnosine chelate compound (Z-103), a novel antioxidant, on acute gastric muco-